Originally published by our sister publication Infectious Disease Special Edition
New START data confirm that starting antiretroviral treatment (ART) early in the course of HIV infection when the immune system is stronger results in better long-term health outcomes compared with delaying ART, according to findings presented at IDWeek 2022, in Washington, D.C.
In 2015, the START (Strategic Timing of Antiretroviral Treatment) study demonstrated a 57% reduced risk for AIDS and serious non-AIDS